Table 5.
Overall survival based on clinicopathological features
| Clinicopathological features | Patients | Events | Median survival (95%CI), mo | P-value |
| Gender | 0.707 | |||
| Male | 640 | 144 | NA | |
| Female | 418 | 100 | NA | |
| Age (yr) | ||||
| ≤ 60 | 522 | 116 | NA | 0.591 |
| > 60 | 536 | 128 | NA | |
| ≤ 65 | 661 | 138 | NA | 0.027 |
| > 65 | 397 | 106 | NA | |
| Tumor site | 0.457 | |||
| Colon | 568 | 133 | NA | |
| Rectal | 490 | 111 | NA | |
| Tumor grade | 0.000 | |||
| 1-2 | 839 | 176 | NA | |
| 3 | 219 | 68 | NA | |
| Histology | 0.000 | |||
| Tubular | 971 | 205 | NA | |
| Mucinous/ Other types | 87 | 39 | 54.90 | |
| Lymph node metastasis | 0.000 | |||
| No | 562 | 61 | NA | |
| Yes | 496 | 183 | NA | |
| Tumor stage | 0.000 | |||
| I-II | 198 | 13 | NA | |
| III-IV | 860 | 231 | NA | |
| HER2 protein overexpression by IHC | ||||
| IHC (-) | 935 | 221 | NA | 0.220 |
| IHC (+) | 123 | 23 | NA | |
| HER2 gene amplification by FISH | ||||
| Positive | 1022 | 234 | NA | 0.458 |
| Negative | 36 | 10 | NA | |
NA: Because the overall survival rates of these patients were more than 50%, we didn’t get the median survival time. HER2: Human epidermal growth factor receptor 2; FISH: Fluorescence in situ hybridization; IHC: Immunohistochemical staining.